臨床薬理
Online ISSN : 1882-8272
Print ISSN : 0388-1601
ISSN-L : 0388-1601
Piretamide (Hoe 118) 経口単回投与時の体内動態
健常人, 慢性腎不全例, 肝硬変症例での検討
藤原 研司尾形 逸郎三代 俊治太田 裕彦林 茂樹山形 陽
著者情報
ジャーナル フリー

1982 年 13 巻 2 号 p. 301-310

詳細
抄録
Serum concentrations, urinary excretion and diuretic effect of piretanide werestudied in 9 subjects (3 healthy volumteers, 3 patients with chronic renal failure and 3 patients with liver cirrhosis) after a single 6mg oral dose. The following results were obtained:
(1) Peak serum concentrations of piretanide were attained within 2 hours after treatment in all subjects. Peak serum concentrations and the AUC of the serum concentration curve did not indicate any marked inter-subject variations in absorption.
(2) The disappearance of piretanide from the serum was prolonged in patients with reduced renal function. After 24 hours, however, no appreciable amounts of piretanide were detected, even in patients with chronic renal failure.
(3) Urinary piretanide excretion was generally completed within 24 hours after treatment in all three groups. The excretion in the renal failure group was, however, lower than in the other two groups.
(4) 24-hour urine volumes were comparable in all three groups. Electrolyte (Na+, K+, Cl-), creatinine and uric acid excretion was lower in the renal failure group.
(5) In the healthy volunteer and liver cirrhosis groups, serum concentrations and urinary excretion of piretanide both closely reflected diuretic effect. In the renal failure group, diuretic activity was only correlated with urinary excretion of piretanide and not with serum concentrations of drug.
著者関連情報
© 日本臨床薬理学会
前の記事 次の記事
feedback
Top